Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Trial to Study the Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma Refractory to Checkpoint Inhibitors

NCT04588051 is registered in ClinicalTrials.gov with Stephen Chan Lam as lead sponsor.

NCT NCT04588051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04588051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Trial to Study the Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma Refractory to Checkpoint Inhibitors
Lead sponsor
Stephen Chan Lam
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 1, 2020
Completion date
December 31, 2028
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hcc